Skip to main content
An official website of the United States government
Email

Current NCI SBIR Contract Solicitation

Program Solicitation PHS 2025-1

The application period is closed [View solicitation].

FY25 NCI SBIR Contract Solicitation Webinar [View recording] 

 

Below were the 13 topics included in the PHS 2025-1 SBIR Contract Solicitation.

  • NIH/NCI 466 - Novel Delivery Systems for RNA-based Cancer Vaccines

  • NIH/NCI 467 - Development of Cancer Immunoprevention Agents

  • NIH/NCI 468 - Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies

  • NIH/NCI 469 - Development of Novel Therapeutics for HPV-related Precancer

  • NIH/NCI 470 - Precision Nutrition Interventions to Reduce Cancer-Related Symptoms

  • NIH/NCI 471 - Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention

  • NIH/NCI 472 - Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer

  • NIH/NCI 473 - Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins in Oropharyngeal Cancer

  • NIH/NCI 474 - Point of Care Technologies for GI Cancer Prevention and Early Detection

  • NIH/NCI 475 - Development of Digital Biomarkers and Endpoints for Clinical Cancer Care

  • NIH/NCI 476 - Digital Twin Software for Optimization of Cancer Radiation Therapy 

  • NIH/NCI 477 - Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment

  • NIH/NCI 478 - Advanced Biomaterials to Improve Cancer Modeling for Research

For additional information, please see the NCI Board of Scientific Advisors (BSA) presentation on the PHS 2025-1 SBIR Contract Solicitation topics.

Applicants must use the Contract Proposal Submission (eCPS) website to submit their proposal. No other method of proposal submission is permitted. Instructions for electronic submission are provided in the solicitation. Actual contract topic numbers will be available in the solicitation.

For more information, contact Tanya Renwick, contract analyst in the Office of Acquisitions, at ncioasbir@mail.nih.gov.

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Current NCI SBIR Contract Solicitation was originally published by the National Cancer Institute.”

Email